ATE124865T1 - Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. - Google Patents

Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.

Info

Publication number
ATE124865T1
ATE124865T1 AT87311079T AT87311079T ATE124865T1 AT E124865 T1 ATE124865 T1 AT E124865T1 AT 87311079 T AT87311079 T AT 87311079T AT 87311079 T AT87311079 T AT 87311079T AT E124865 T1 ATE124865 T1 AT E124865T1
Authority
AT
Austria
Prior art keywords
consciousness
heterocyclic compounds
treat disorders
disorders
attentional
Prior art date
Application number
AT87311079T
Other languages
English (en)
Inventor
Michael Brian Tyers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE124865T1 publication Critical patent/ATE124865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87311079T 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. ATE124865T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (1)

Publication Number Publication Date
ATE124865T1 true ATE124865T1 (de) 1995-07-15

Family

ID=27449858

Family Applications (2)

Application Number Title Priority Date Filing Date
AT87311079T ATE124865T1 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln

Country Status (7)

Country Link
US (1) US4985437A (de)
EP (3) EP0279990B1 (de)
JP (1) JP2608079B2 (de)
AT (2) ATE124865T1 (de)
DE (2) DE3752062T2 (de)
ES (1) ES2074981T3 (de)
GR (1) GR3017369T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
US4948803A (en) * 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
WO1990014347A1 (fr) * 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
DE69111816T4 (de) * 1990-08-31 1996-08-01 Nippon Shinyaku Co Ltd Indolederivate und ihre verwendung als serotonin-antagoniste.
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
CN1118990A (zh) * 1993-03-08 1996-03-20 藤泽药品工业株式会社 治疗或预防脑血管疾病药物
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0212477A (pt) * 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
MXPA04003007A (es) 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2003070732A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1478646A1 (de) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclische verbindungen mit activität an alfa7 nikotinischen acetylcholin rezeptoren
JP2006506395A (ja) * 2002-11-01 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
DE3587151T2 (de) * 1984-12-20 1993-07-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
EP0247266B1 (de) * 1986-01-07 1993-03-10 Beecham Group Plc Indolderivate mit einer azabicyclischen Seitenkette, Verfahren zu ihrer Herstellung, Zwischenprodukte und pharmazeutische Zusammensetzungen
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
ATE101117T1 (de) * 1988-05-16 1994-02-15 Searle & Co 2-amino-4,5-methylenadipinsaeure-verbindungen fuer die behandlung von cns-erkrankungen.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
EP0495831B1 (de) * 1989-10-16 1997-01-15 Hem Pharmaceuticals Corp. Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch-immunologischer fehlfunktion
JPH0747585B2 (ja) * 1990-05-11 1995-05-24 三共株式会社 イソオキサゾール誘導体

Also Published As

Publication number Publication date
ATE152623T1 (de) 1997-05-15
DE3752062D1 (de) 1997-06-12
DE3751404T2 (de) 1995-12-21
GR3017369T3 (en) 1995-12-31
EP0551963A2 (de) 1993-07-21
DE3752062T2 (de) 1997-09-11
DE3751404D1 (de) 1995-08-17
JP2608079B2 (ja) 1997-05-07
EP0279990B1 (de) 1995-07-12
ES2074981T3 (es) 1995-10-01
EP0559297B1 (de) 1997-05-07
EP0559297A1 (de) 1993-09-08
EP0279990A2 (de) 1988-08-31
JPS63277623A (ja) 1988-11-15
EP0279990A3 (en) 1990-11-28
US4985437A (en) 1991-01-15
EP0551963A3 (en) 1993-09-01

Similar Documents

Publication Publication Date Title
ATE124865T1 (de) Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
BR9206500A (pt) Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
DE69941154D1 (de) Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE3686622D1 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
DE3689099D1 (de) Verwendung von angiotensin-converting-enzym-inhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
BG103089A (en) Indoline derivatives useful as 5-ht-2c-receptor antagonists
ATE89722T1 (de) Verwendung von betablockern zur behandlung der progression der kindlichen achsenmyopie.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee